List of Excipients in Branded Drug MEROPENEM AND SODIUM CHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	MEROPENEM AND SODIUM CHLORIDE	meropenem and sodium chloride	0264-3183	SODIUM CARBONATE
B Braun Medical Inc	MEROPENEM AND SODIUM CHLORIDE	meropenem and sodium chloride	0264-3183	SODIUM CHLORIDE
B Braun Medical Inc	MEROPENEM AND SODIUM CHLORIDE	meropenem and sodium chloride	0264-3183	WATER

Meropenem and Sodium Chloride Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 26, 2026

Meropenem and sodium chloride is a mature sterile injectable combination with limited conventional patent protection but meaningful product-development opportunities. The commercial opportunity is concentrated in ready-to-use intravenous presentations, improved refrigerated or room-temperature stability, reduced pharmacy compounding, pediatric dose flexibility, container innovation, and lower total cost of administration. Meropenem is the active pharmaceutical ingredient; sodium chloride 0.9% functions primarily as the intravenous diluent and tonicity agent.

What is the formulation strategy for meropenem and sodium chloride?

Meropenem is a broad-spectrum carbapenem administered by intravenous injection or infusion. Commercial products generally contain meropenem trihydrate equivalent to anhydrous meropenem, with excipients such as sodium carbonate in the sterile powder formulation. Sodium chloride is used in the final infusion solution at approximately 0.9% w/v when the drug is supplied as a premixed intravenous product.[1]

Component	Formulation role	Key development issue
Meropenem	Active antibiotic	Hydrolytic and temperature-sensitive stability in solution
Sodium chloride	Tonicity agent and infusion vehicle	Osmolality, compatibility, container interaction
Sodium carbonate or equivalent alkalinizing agent	pH control in powder formulations	Reconstitution, chemical stability, local tolerability
Water for Injection	Solvent for reconstitution	Sterility, endotoxin control, final volume
Container closure system	Product protection and administration	Extractables, leachables, oxygen and moisture transmission

The main technical challenge is that meropenem is materially less stable after dissolution than in its dry powder state. A formulation strategy therefore must balance rapid dissolution, acceptable pH, chemical stability, microbial control, and practical hospital handling.

Which excipients are technically relevant?

The most defensible excipient platform is a low-excipient formulation based on:

1. Meropenem trihydrate.
2. A controlled amount of sodium carbonate or another approved alkalinizing system.
3. Sterile water for reconstitution.
4. Sodium chloride 0.9% as the final infusion vehicle.

Additional excipients are generally unattractive unless they solve a specific problem. Antioxidants, surfactants, preservatives, or complexing agents can create new regulatory and compatibility risks in a high-volume parenteral antibiotic. A ready-to-use product should minimize formulation complexity because hospitals value predictable compatibility and rapid administration.

What formulations are protected by meropenem and sodium chloride patents?

The original meropenem substance and basic injectable formulation are mature technologies. The principal commercial protection for branded meropenem products has expired in major markets. Current differentiation is more likely to arise from formulation, container, manufacturing, stability, or delivery-system claims than from the active ingredient.

Potentially protectable subject matter includes:

• A stable meropenem solution in 0.9% sodium chloride.
• Defined meropenem concentration ranges, such as 5 mg/mL or 10 mg/mL.
• Room-temperature storage for a specified period.
• Frozen or refrigerated premixed bags with controlled thawing conditions.
• Low-oxygen filling and packaging.
• Specific sodium carbonate-to-meropenem ratios.
• Dual-chamber bags separating dry meropenem from sodium chloride until use.
• Elastomeric infusion devices containing meropenem and sodium chloride.
• Pediatric or neonatal dose presentations.
• Manufacturing processes that reduce degradation products.
• Container closure systems that limit oxygen ingress or adsorption.

A formulation patent is strongest when it claims a measurable technical result, such as a defined impurity profile after a specified storage period, rather than merely claiming meropenem in normal saline.

When does meropenem lose exclusivity?

Meropenem lost core small-molecule exclusivity years ago. Merrem, the original branded product, was approved by the FDA in 1996. The active ingredient is now marketed by multiple generic manufacturers under abbreviated new drug applications.[1,2]

Exclusivity category	Current commercial position
New chemical entity exclusivity	Expired
Original compound patent protection	Expired in major markets
Pediatric exclusivity	Expired
Orphan exclusivity	Not the principal protection for standard meropenem injection
Biosimilar exclusivity	Not applicable
Generic competition	Established
Product-specific formulation protection	Depends on individual patent and jurisdiction

The relevant commercial question is no longer whether the basic meropenem molecule is protected. It is whether a specific ready-to-use presentation has enforceable formulation, device, manufacturing, or method-of-use claims.

What is the Orange Book status of meropenem and sodium chloride?

Meropenem injection is regulated as a conventional small-molecule sterile drug. An ANDA is generally the expected pathway for a product that matches the reference product in active ingredient, dosage form, route, strength, and applicable performance characteristics.[3]

The FDA Orange Book should be reviewed by reference product, strength, and dosage form because listings can differ between:

• Meropenem powder for injection.
• Meropenem premixed in sodium chloride.
• Different container sizes.
• Products with distinct reference listed drugs.
• Method-of-use patents, if any are listed for a particular product.

For the mature generic meropenem market, the principal regulatory barrier is usually pharmaceutical equivalence, sterility, stability, and manufacturing validation rather than active-ingredient patent infringement. An applicant should not assume that the absence of a listed patent eliminates all litigation risk. Non-Orange Book patents covering a device, manufacturing process, or commercial packaging can still create disputes, although their ability to block FDA approval differs from listed drug patents.

How many patents cover meropenem and sodium chloride products?

There is no meaningful single patent count for the combination. The answer depends on the exact product architecture and jurisdiction.

Patent category	Relevance to a standard meropenem injection	Commercial risk
Meropenem composition-of-matter patents	Low; generally expired	Low
Basic powder formulation patents	Low to moderate	Usually low if expired
Sodium chloride vehicle claims	Low	Low
Premixed solution stability claims	Moderate	Product-specific
Dual-chamber container claims	Moderate to high	Can affect launch design
Elastomeric pump claims	Moderate	Device and combination-product risk
Manufacturing-process claims	Moderate	Depends on process overlap
Method-of-use claims	Low to moderate	Relevant only to claimed indications or dosing
Packaging and oxygen-control claims	Moderate	Often avoidable through design-around

A freedom-to-operate review should focus on active U.S., European, Chinese, Japanese, and other target-market patents claiming the exact concentration, storage condition, bag architecture, filling method, or administration device.

What is the stability challenge in meropenem sodium chloride products?

Meropenem stability in solution is the central technical constraint. Degradation can increase with temperature, time, unsuitable pH, light exposure, oxygen exposure, and repeated temperature cycling. The product must be evaluated for assay, related substances, particulate matter, color, pH, osmolality, sterility, and container integrity.

A development program should compare at least the following:

Variable	Development question
Meropenem concentration	Does higher concentration accelerate degradation or precipitation?
Sodium chloride concentration	Is 0.9% sodium chloride optimal for tonicity and stability?
pH	Does the alkalinizing system preserve potency without increasing irritation?
Temperature	Can the product remain usable at controlled room temperature?
Light	Is an overwrap or opaque container necessary?
Oxygen	Does nitrogen purging or low-headspace filling reduce impurities?
Container	Does the bag or bottle contribute extractables or adsorption?
Freeze-thaw	Can frozen inventory be transported and thawed without potency loss?

The label-supported in-use period should be established separately from unopened shelf life. A commercial product may have a long refrigerated shelf life but a short post-reconstitution or post-thaw administration window.

What commercial opportunities exist for meropenem and sodium chloride?

The highest-value opportunity is a ready-to-use premixed intravenous product that reduces pharmacy preparation. The product can compete on workflow, waste reduction, storage flexibility, and supply reliability rather than on molecule-level efficacy.

Ready-to-use hospital bags

Premixed bags can reduce:

• Pharmacy compounding labor.
• Reconstitution errors.
• Exposure to powdered antibiotics.
• Manipulation of sterile connections.
• Delays in emergency antibiotic administration.
• Waste from partially used vials.

A practical portfolio would include 500 mg and 1 g presentations, subject to target-market labeling and hospital demand. Smaller-volume presentations may support pediatrics and dose-banded adult use.

Extended-stability products

A product with validated stability for a longer period after preparation can support:

• Emergency departments.
• Intensive-care units.
• Operating rooms.
• Emergency medical services.
• Home infusion.
• Outpatient parenteral antimicrobial therapy.

The commercial value increases if the product can be stored under less restrictive conditions without compromising potency or impurity limits.

Dual-chamber systems

A dual-chamber bag separates dry meropenem from sodium chloride until activation. This design addresses the main chemical-stability problem while retaining ready-to-administer convenience.

Advantages include:

• Longer unopened shelf life than a fully dissolved product.
• Reduced reconstitution steps.
• Lower risk of incorrect diluent selection.
• Compatibility with hospital infusion workflows.

The disadvantages are higher packaging cost, more complex manufacturing, device validation, and possible combination-product regulation.

Elastomeric and ambulatory infusion systems

Meropenem is relevant to outpatient and home-infusion markets, particularly for severe bacterial infections requiring repeated daily administration or prolonged infusion strategies. A prefilled elastomeric device could provide a differentiated product if it demonstrates acceptable stability during storage, transport, and administration.

The patent and regulatory profile is more complicated because the product can implicate both drug and device requirements. The value proposition is strongest where reduced nursing time and patient travel offset the higher device cost.

How does meropenem compare with competing carbapenem products?

Meropenem competes with other hospital antibiotics, not only with other meropenem products. Its commercial position is shaped by spectrum, dosing convenience, resistance patterns, supply reliability, and total administration cost.

Product	Formulation opportunity	Key competitive factor
Meropenem	Premixed sodium chloride bag, dual-chamber bag, ambulatory device	Broad hospital use and established generic supply
Imipenem/cilastatin	Reconstituted injectable products	Established alternative but different dosing and tolerability profile
Ertapenem	Powder for injection and infusion	Once-daily convenience
Doripenem	Limited commercial relevance in many markets	Narrower current opportunity
Ceftazidime/avibactam and other newer agents	Proprietary combination products	Higher pricing but distinct resistance coverage

A meropenem premix must compete against low-cost generic vials. The product needs to demonstrate a measurable economic benefit, such as fewer preparation steps, reduced waste, lower error risk, or improved availability.

Which companies are challenging or competing with meropenem products?

Competition is fragmented among generic injectable manufacturers, branded hospital suppliers, contract manufacturers, and regional sterile-product companies. Relevant competitor types include:

• Generic manufacturers with approved meropenem vials.
• Branded generic suppliers with institutional contracts.
• Sterile injectable specialists.
• Hospital-system compounders.
• Premix and infusion-device companies.
• Contract development and manufacturing organizations.

The competitive barrier is manufacturing execution. A company with an approved vial may still lack the aseptic filling, bag assembly, device integration, and stability package required for a commercial premix.

What generic entry risks exist for a new meropenem sodium chloride product?

Generic entry risk is high for conventional vial products because the market is mature and price competition is established. A differentiated sodium chloride product faces lower direct substitution risk only if its delivery benefits are meaningful.

Principal risks include:

1. Price erosion from established generic suppliers.
2. Hospital formularies that treat vial and premix products as therapeutically interchangeable.
3. Limited willingness to pay for pharmacy labor savings.
4. Short in-use stability that reduces the product's operational advantage.
5. Manufacturing failures in aseptic filling or container closure.
6. Drug shortages that shift demand unpredictably.
7. Procurement concentration among group purchasing organizations.
8. Device or packaging patents affecting the preferred presentation.
9. Regulatory delay caused by complex stability or combination-product requirements.
10. Supply-chain dependence on meropenem API and sterile components.

A differentiated product should target hospitals with high antibiotic utilization, limited pharmacy compounding capacity, or established premix purchasing protocols.

What patent litigation affects meropenem and sodium chloride products?

Core meropenem patent litigation is unlikely to be the main barrier for a standard generic injection because the molecule and original product technology are mature. Litigation risk is more likely to arise from:

• A newly developed premix formulation.
• A dual-chamber bag.
• A proprietary elastomeric pump.
• A manufacturing process.
• A packaging system.
• A method-of-use claim tied to prolonged infusion or a specific dosing regimen.

A Paragraph IV certification is relevant only when an ANDA applicant addresses an unexpired patent listed for the reference product. For a product with no relevant unexpired Orange Book patent, the applicant may instead rely on Paragraph III, Paragraph IV, or a certification structure appropriate to the listed patents and regulatory record.[3,4]

Settlement agreements are not a standard feature of the mature basic-meropenem market. They become more relevant if a sponsor obtains a new formulation patent and a generic applicant files an ANDA with a Paragraph IV certification.

What FDA regulatory pathway applies to meropenem sodium chloride?

The pathway depends on the product design.

Product design	Likely regulatory approach
Same powder vial as reference product	ANDA, subject to pharmaceutical equivalence
Premixed solution with an established reference product	ANDA if equivalence and product-specific requirements can be met
New stability profile or novel formulation	ANDA or 505(b)(2), depending on differences and FDA precedent
Dual-chamber bag	ANDA or 505(b)(2), with device and container validation
Prefilled elastomeric pump	Potential combination-product review
New dosing regimen or clinical use	May require additional clinical and regulatory support

FDA review will focus on sterility assurance, particulate control, extractables and leachables, container closure integrity, stability-indicating methods, degradation products, compatibility with administration sets, and labeling of storage and in-use conditions.[1,5]

How strong is the patent estate for meropenem sodium chloride?

The patent estate is weak for the active ingredient and standard vial but can be moderate for a genuinely differentiated delivery system.

Product concept	Patent strength	Commercial defensibility
Meropenem powder vial	Low	Low
Meropenem in standard 0.9% sodium chloride	Low to moderate	Low unless stability is unexpected
Extended-stability premix	Moderate	Depends on data and claim scope
Dual-chamber bag	Moderate to high	Stronger if claims cover activation and stability
Prefilled elastomeric device	Moderate	Depends on drug-device integration
Low-oxygen filling process	Moderate	Potentially narrow but useful
Pediatric ready-to-use doses	Low to moderate	More regulatory and commercial than patent-driven

A strong patent filing should include composition, concentration, pH, impurity limits, storage conditions, container specifications, and comparative stability data. Method-of-treatment claims can supplement, but they are unlikely to provide the primary commercial moat for a mature hospital antibiotic.

What are the geographic opportunities for meropenem sodium chloride products?

The United States offers a large institutional market but has demanding regulatory, procurement, and supply requirements. Europe rewards standardized hospital presentations and centralized procurement. Emerging markets may offer stronger demand for affordable carbapenems but can impose lower prices and greater supply-chain volatility.

Priority markets should be screened against:

• Hospital injectable antibiotic volume.
• Local approval pathway.
• Prevalence of hospital-acquired infections.
• Premix adoption.
• Cold-chain requirements.
• Public procurement pricing.
• Local manufacturing incentives.
• Carbapenem stewardship policies.
• Patent status and regulatory exclusivity.
• Availability of approved meropenem reference products.

A product designed for global commercialization should avoid unnecessary dependence on frozen distribution. Refrigerated or controlled-room-temperature stability creates more addressable markets than a product requiring specialized logistics.

What revenue exposure and launch scenarios apply?

Meropenem is generally a high-volume, lower-margin hospital antibiotic. Revenue depends more on contract access and supply reliability than on branded price premiums.

Launch scenario	Product profile	Expected commercial position
Standard generic vial	Lowest development complexity	High price pressure
Premixed 500 mg and 1 g bags	Moderate complexity	Better pharmacy-workflow value
Extended-stability premix	Higher technical risk	Potential institutional premium
Dual-chamber bag	High packaging complexity	Strong differentiation if shelf life improves
Home-infusion device	High device and regulatory complexity	Smaller but higher-value segment
Pediatric ready-to-use product	Moderate complexity	Niche demand and dosing convenience

The largest near-term opportunity is a hospital premix that can be supplied at a modest premium to vials while producing documented reductions in compounding labor and preparation time. A high-priced product without operational evidence is vulnerable to formulary rejection.

Key Takeaways

• Meropenem is a mature generic small molecule with expired core exclusivity in major markets.
• Sodium chloride 0.9% is primarily the infusion vehicle and tonicity agent, not the source of active pharmaceutical protection.
• The main technical issue is meropenem degradation after dissolution.
• Standard vials face intense price competition and have limited patent differentiation.
• Premixed bags, dual-chamber systems, extended-stability formulations, and ambulatory infusion devices offer the strongest commercial opportunities.
• Patent value is concentrated in stability, packaging, manufacturing, and drug-device claims.
• Paragraph IV risk is product-specific and depends on current Orange Book listings.
• FDA success requires a robust stability, sterility, container-closure, and extractables/leachables package.
• The most credible launch strategy is a 500 mg and 1 g ready-to-use sodium chloride presentation targeted at institutional hospitals and outpatient infusion providers.

FAQs

Can meropenem be formulated in sodium chloride instead of sterile water?

Yes. Sodium chloride 0.9% is a standard intravenous diluent for meropenem when the product labeling supports that use. Compatibility and storage limits must be established for the specific concentration and container.

Is sodium chloride a patentable excipient for meropenem?

Sodium chloride itself generally provides little patent value in this context. Patentability is more likely to arise from the complete formulation, concentration, stability result, container system, or manufacturing process.

Does meropenem have biosimilar competition?

No. Meropenem is a chemically synthesized small-molecule antibiotic. Competition proceeds through generic drug pathways rather than biosimilar applications.

Is a premixed meropenem bag eligible for an ANDA?

It may be, if the product can demonstrate the required sameness or equivalence to an appropriate reference product and satisfy FDA requirements for the formulation, container, stability, and administration system. A materially different product may require a 505(b)(2) pathway.

What is the strongest commercial differentiator for meropenem sodium chloride?

The strongest differentiator is a validated ready-to-use product with longer practical storage and in-use stability, low preparation burden, broad administration-set compatibility, and a cost that remains competitive with vial-based compounding.

References

1. U.S. Food and Drug Administration. (2024). Meropenem for injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (1996). Merrem I.V. approval history and prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapters for sterile products, particulate matter, and container closure integrity. United States Pharmacopeial Convention.